• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Low Prevalence of Endoscopic Screening for Barrett's Esophagus in a Screening-Eligible Primary Care Population.筛查合格的初级保健人群中 Barrett 食管内镜筛查的患病率较低。
Am J Gastroenterol. 2022 Nov 1;117(11):1764-1771. doi: 10.14309/ajg.0000000000001935. Epub 2022 Aug 12.
2
Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma.食管腺癌退伍军人中 Barrett 食管筛查和监测的错失机会。
Dig Dis Sci. 2019 Feb;64(2):367-372. doi: 10.1007/s10620-018-5336-5. Epub 2018 Oct 28.
3
Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.与典型的胃食管反流症状相比,喉咽反流症状能更好地预测食管腺癌的存在。
Ann Surg. 2004 Jun;239(6):849-56; discussion 856-8. doi: 10.1097/01.sla.0000128303.05898.ee.
4
Gastroesophageal Reflux Disease Is Not a Great Screening Criterion: Time to Move on to Other Strategies for Controlling the Burden of Esophageal Adenocarcinoma.胃食管反流病不是一个很好的筛查标准:是时候转向其他策略来控制食管腺癌的负担了。
Am J Gastroenterol. 2022 Nov 1;117(11):1759-1761. doi: 10.14309/ajg.0000000000001998. Epub 2022 Sep 26.
5
Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.胃食管反流病、质子泵抑制剂使用与食管腺癌中的 Barrett 食管:重新审视趋势。
Surgery. 2013 Oct;154(4):856-64; discussion 864-6. doi: 10.1016/j.surg.2013.07.020.
6
Prevalence and Predictors of Barrett's Esophagus After Negative Initial Endoscopy: Analysis From Two National Databases.初次内镜阴性后 Barrett 食管的流行率及其预测因素:来自两个国家数据库的分析。
Clin Gastroenterol Hepatol. 2024 Mar;22(3):523-531.e3. doi: 10.1016/j.cgh.2023.08.035. Epub 2023 Sep 15.
7
Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.胃食管反流病症状患者经经验性质子泵抑制剂治疗失败后的多模态评估。
Dis Esophagus. 2013 Jul;26(5):443-50. doi: 10.1111/j.1442-2050.2012.01381.x. Epub 2012 Aug 2.
8
LOW PREVALENCE OF BARRETT'S ESOPHAGUS IN A RISK AREA FOR ESOPHAGEAL CANCER IN SOUTH OF BRAZIL.巴雷特食管在巴西南部食管癌风险地区的低患病率
Arq Gastroenterol. 2017 Dec;54(4):305-307. doi: 10.1590/S0004-2803.201700000-45. Epub 2017 Sep 21.
9
Missed Opportunities: the Timing and Frequency of Screening Colonoscopy in Patients That Develop Esophageal Adenocarcinoma.错失的机会:发生食管腺癌患者的筛查结肠镜检查的时机和频率。
J Gastrointest Surg. 2023 Dec;27(12):2711-2717. doi: 10.1007/s11605-023-05874-8. Epub 2023 Nov 6.
10
Prevalence of Barrett's Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis.巴雷特食管和伴有或不伴有胃食管反流的食管腺癌的流行情况:系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2024 Jul;22(7):1381-1394.e7. doi: 10.1016/j.cgh.2023.10.006. Epub 2023 Oct 24.

引用本文的文献

1
New Approaches to Screening for Barrett Esophagus.巴雷特食管筛查的新方法。
Gastroenterol Hepatol (N Y). 2025 Jun;21(6):353-361.
2
EMERALD in the making? A promising blood-based microRNA panel to detect oesophageal adenocarcinoma and Barrett's oesophagus.正在形成的“翡翠计划”?一种有前景的基于血液的微小RNA检测组合用于检测食管腺癌和巴雷特食管。
Gut. 2025 Jan 28. doi: 10.1136/gutjnl-2025-334795.
3
Real-World Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-Balloon for Detection of Barrett's Esophagus (BE).甲基化DNA生物标志物检测法对吞咽式胶囊球囊采集样本检测巴雷特食管(BE)的真实世界临床效用
Medicina (Kaunas). 2024 Dec 13;60(12):2052. doi: 10.3390/medicina60122052.
4
Acceptability of Nonendoscopic Barrett Esophagus Screening in the Population: Some Initial Promising Answers.非内镜下巴雷特食管筛查在人群中的可接受性:一些初步的、有前景的答案。
Am J Gastroenterol. 2024 Sep 1;119(9):1800-1801. doi: 10.14309/ajg.0000000000002835. Epub 2024 May 3.
5
New Techniques to Screen for Barrett Esophagus.筛查巴雷特食管的新技术。
Gastroenterol Hepatol (N Y). 2023 Jul;19(7):383-390.
6
Development of Electronic Health Record-Based Machine Learning Models to Predict Barrett's Esophagus and Esophageal Adenocarcinoma Risk.基于电子健康记录的机器学习模型在预测巴雷特食管和食管腺癌风险中的开发。
Clin Transl Gastroenterol. 2023 Oct 1;14(10):e00637. doi: 10.14309/ctg.0000000000000637.
7
Predicting Incident Adenocarcinoma of the Esophagus or Gastric Cardia Using Machine Learning of Electronic Health Records.基于电子健康记录的机器学习预测食管或胃贲门部腺癌。
Gastroenterology. 2023 Dec;165(6):1420-1429.e10. doi: 10.1053/j.gastro.2023.08.011. Epub 2023 Aug 18.
8
Construction of the Interaction Network of Hub Genes in the Progression of Barrett's Esophagus to Esophageal Adenocarcinoma.巴雷特食管进展为食管腺癌过程中枢纽基因相互作用网络的构建
J Inflamm Res. 2023 Apr 12;16:1533-1551. doi: 10.2147/JIR.S403928. eCollection 2023.
9
Screening for Barrett oesophagus - a call for collaboration between gastroenterology and primary care.巴雷特食管的筛查——呼吁胃肠病学与基层医疗之间开展合作。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):342-343. doi: 10.1038/s41575-023-00773-4.
10
Estimated Burden of Screening for Barrett's Esophagus in the United States.美国巴雷特食管筛查的估计负担
Gastroenterology. 2023 Jul;165(1):283-285.e2. doi: 10.1053/j.gastro.2023.03.223. Epub 2023 Mar 30.

筛查合格的初级保健人群中 Barrett 食管内镜筛查的患病率较低。

Low Prevalence of Endoscopic Screening for Barrett's Esophagus in a Screening-Eligible Primary Care Population.

机构信息

Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

出版信息

Am J Gastroenterol. 2022 Nov 1;117(11):1764-1771. doi: 10.14309/ajg.0000000000001935. Epub 2022 Aug 12.

DOI:10.14309/ajg.0000000000001935
PMID:35971219
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9633338/
Abstract

INTRODUCTION

Despite societal recommendations supporting Barrett's esophagus (BE) screening, it is unknown what proportion of eligible patients is screened in primary care. We assessed the proportion of BE screening- eligible patients evaluated in the primary care setting receiving upper esophagogastroduodenoscopy (EGD) and identified factors associated with undergoing EGD.

METHODS

This was a retrospective study of BE screening-eligible patients, as defined by the American College of Gastroenterology's BE guidelines, in a multipractice healthcare network consisting of 64 internal medicine practices and 94 family medicine (FM) practices. The proportion undergoing EGD, prevalence of BE and esophageal adenocarcinoma (EAC) in this group, and patient and provider factors associated with undergoing EGD were assessed. Multivariable logistic regression was performed to identify independent predictors of undergoing EGD.

RESULTS

Of 1,127 screening-eligible patients, the mean age was 65.2 ± 8.6 years; 45% were obese; and 61% were smokers. Seventy-three percent were seeing FM; 94% were on proton pump inhibitors; and 44% took ≥1 gastroesophageal reflux disease (GERD) medication. Only 39% of patients (n = 436) had undergone EGD. The overall prevalence of BE or EAC was 9.9%. Of 39 (9%) referred for BE screening as the primary indication, BE/EAC prevalence was 35.1%. Factors associated with increased odds of having EGD were symptomatic GERD despite treatment (odds ratio [OR] 12.1, 95% confidence interval [CI] 9.1-16.3), being on ≥1 GERD medication (OR 1.4, 95% CI 1.0-1.9), and being an FM patient (OR 1.5, 95% CI 1.1-2.1).

DISCUSSION

In this large, primary care population, only 39% of screening-eligible patients underwent EGD. Most of the examinations were triggered by refractory symptoms rather than screening referrals, highlighting a need for improved dissemination and implementation of BE screening.

摘要

简介

尽管社会建议支持 Barrett 食管(BE)筛查,但尚不清楚在初级保健中筛查了多少符合条件的患者。我们评估了在初级保健环境中评估的 BE 筛查合格患者中接受上食管胃十二指肠镜检查(EGD)的比例,并确定了与进行 EGD 相关的因素。

方法

这是一项针对符合美国胃肠病学院 BE 指南定义的 BE 筛查合格患者的回顾性研究,这些患者来自一个由 64 个内科实践和 94 个家庭医学(FM)实践组成的多实践医疗网络。评估了该组患者中接受 EGD 的比例、BE 和食管腺癌(EAC)的患病率,以及与接受 EGD 相关的患者和提供者因素。进行多变量逻辑回归以确定接受 EGD 的独立预测因素。

结果

在 1127 名筛查合格的患者中,平均年龄为 65.2±8.6 岁;45%为肥胖;61%为吸烟者。73%的患者在看 FM;94%的患者在服用质子泵抑制剂;44%的患者服用≥1 种胃食管反流病(GERD)药物。只有 39%的患者(n=436)接受了 EGD。总的 BE 或 EAC 患病率为 9.9%。在作为主要指征进行 BE 筛查的 39 名(9%)患者中,BE/EAC 的患病率为 35.1%。与接受 EGD 几率增加相关的因素包括尽管接受了治疗,但 GERD 症状仍存在(比值比[OR] 12.1,95%置信区间[CI] 9.1-16.3)、服用≥1 种 GERD 药物(OR 1.4,95% CI 1.0-1.9)和是 FM 患者(OR 1.5,95% CI 1.1-2.1)。

讨论

在这个大型的初级保健人群中,只有 39%的筛查合格患者接受了 EGD。大多数检查是由难治性症状引发的,而不是筛查转诊,这突出表明需要改进 BE 筛查的传播和实施。